WHO Media
| Friday, 29 September 2023 News Release
The World Health Organization (WHO) today announced the recommendations for the viral composition of influenza vaccines for the 2024 influenza season in the southern hemisphere. The announcement was made at an information session at the end of a 4-day meeting on the Composition of Influenza Virus Vaccines, a meeting that is held twice annually.
WHO organizes these consultations with an advisory group of experts gathered from WHO Collaborating Centres and WHO Essential Regulatory Laboratories to analyse influenza virus surveillance data generated by the WHO Global Influenza Surveillance and Response System (GISRS). The recommendations issued are used by the national vaccine regulatory agencies and pharmaceutical companies to develop, produce, and license influenza vaccines for the following influenza season. The periodic update of viruses contained in influenza vaccines is necessary for the vaccines to be effective due to the constant evolving nature of influenza viruses, including those circulating and infecting humans. The WHO recommends that trivalent vaccines for use in the 2024 southern hemisphere influenza season contain the following: Egg-based vaccines - an A/Victoria/4897/2022 (H1N1)pdm09-like virus;
- an A/Thailand/8/2022 (H3N2)-like virus; and
- a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
Cell culture- or recombinant-based vaccines
- an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;
- an A/Massachusetts/18/2022 (H3N2)-like virus; and
- a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
For quadrivalent egg- or cell culture-based or recombinant vaccines for use in 2024 southern hemisphere influenza season, the WHO recommends inclusion of the following B/Yamagata lineage component:
- a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
Related links: ./.  POST VPC AUDIO FILE Please find below link to the audio files from the Virtual Press Conference held today, Friday 29 September, at 13:30hrs/1:30pm local time, at WHO headquarters in Geneva.Press conference: https://who.canto.global/b/KPP0T
Speakers were:
- Dr Sylvie BRIAND, Director, WHO Director, Epidemic and Pandemic Preparedness and Prevention
- Dr Wenqing ZHANG, Head, WHO Global Influenza Programme (GIP)
- Dr Kanta SUBBARAO, Director, WHO Collaborating Centre for Reference and Research on Influenza, Victoria Infectious Diseases Reference Laboratory (VIDRL), Australia
- Dr Richard WEBBY, Director, WHO Collaborating Centre for Studies on the Ecology of Influenza in Animals, Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, USA
- Dr David WENTWORTH, Director, WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza, Centers for Disease Control and Prevention (CDC), USA
./. You are receiving this NO-REPLY email because you are included on a WHO mail list.
If you have been forwarded this update you can click here to subscribe.
Journalists may send feedback to WHO Media Team |
No comments:
Post a Comment
Keep a civil tongue.